Drug discovery & regenerative medicine

From thousands of molecules to the few that matter

Dhar Biosciences discovers and develops medicines for diseases that need better treatments. We pair strong disease biology with careful screening and medicinal chemistry, and we advance only the candidates the data supports.

Plate 05 384-well primary screen · 10 µM
Hits
7
Hit rate
2.2%
Z′
0.81
Simulated primary screen. The outer columns hold positive and negative controls; a hit is any compound well at 50% inhibition or higher. Hover or tap a well to read it.

Approach

Every program earns its next step.

Drug discovery is a long sequence of decisions. We define the evidence a program needs before it moves forward, and we hold to it.

  1. Target validation

    We start with targets that have strong human evidence linking them to disease, then confirm the biology in cell systems that reflect the patient.

    → Validated target
  2. Hit finding

    We screen broadly and confirm carefully. Every hit is retested in dose response and checked in an orthogonal assay before chemistry begins.

    → Confirmed hit series
  3. Lead optimization

    Medicinal chemists improve potency, selectivity, and drug-like properties together, guided by structure and by measured data on every new analog.

    → Optimized lead
  4. Candidate selection

    A molecule becomes a development candidate when its efficacy, exposure, and safety data make a convincing case for the clinic.

    → Development candidate

Science

Most programs fail late. We work to find out early.

A single-concentration screen finds starting points. A full dose–response curve tells us whether a compound is worth pursuing. We measure the properties that end programs as early as we can, so our effort goes to molecules with a real chance in the clinic.

Potency
IC₅₀ and EC₅₀ in biochemical and cellular assays
Selectivity
Counter-screens against related targets and a broad safety panel
Exposure
ADME and pharmacokinetics from the earliest analogs
Safety
In vitro toxicity flags before any in vivo study
Target IC₅₀ 40 nM Off-target IC₅₀ 6.3 µM
Illustrative data. The horizontal gap between the two curves at 50% inhibition is the selectivity window: how much more compound it takes to hit the off-target.

Regenerative medicine

Mesenchymal stem cells, measured like medicines.

Mesenchymal stem cells (MSCs) are adult stromal cells found in bone marrow, fat, and umbilical cord tissue. They can calm harmful inflammation and help damaged tissue recover, mostly through the signals they release. Our regenerative medicine program develops MSC therapies with the same standards of evidence we apply to drug discovery.

How MSCs work

Immune balance
MSCs damp overactive T-cell and macrophage responses through mediators such as PGE₂, IDO, and TGF-β.
Tissue repair
Growth factors and extracellular vesicles released by MSCs can support new blood vessel growth and help injured cells survive.
Differentiation
In culture, MSCs can become bone, cartilage, and fat cells. This is one of the defining tests of MSC identity.

Every lot we make is tested for identity, viability, sterility, and potency before it is used in a study.

Identity panel Example lot · flow cytometry
Positive markers · ≥95% of cellsPass
CD7399.1%
CD9098.6%
CD10597.8%
Negative markers · ≤2% of cellsPass
CD450.4%
CD340.7%
CD140.3%
CD190.2%
HLA-DR0.9%
Release thresholds (dark ticks) follow the ISCT minimal criteria for MSCs: plastic adherence, CD73, CD90, and CD105 on at least 95% of cells, CD45, CD34, CD14 or CD11b, CD79α or CD19, and HLA-DR on no more than 2%, and tri-lineage differentiation. Values shown are illustrative.

Tri-lineage potential

Each lot is induced toward bone, fat, and cartilage, then stained to confirm the result. Shown here as illustrations of typical staining.

  • BoneAlizarin Red S · calcium deposits
  • FatOil Red O · lipid droplets
  • CartilageAlcian Blue · proteoglycan matrix

Investigational. Our MSC therapies are in development and have not been approved by the FDA or any other regulator. We do not provide them as treatments outside of authorized clinical studies.

Pipeline

Programs where patients need more options.

Our programs are at different stages of discovery and development. We update this page as they reach new milestones.

Drug discovery 3 programs

  1. DB-101

    Oncology

    Solid tumors

    IND-enabling
  2. DB-204

    Immunology

    Autoimmune and inflammatory disease

    Lead optimization
  3. DB-312

    Neuroscience

    Neurodegenerative disease

    Discovery

Cell therapy Mesenchymal stem cells · 1 program

  1. DBM-101

    Musculoskeletal

    Knee osteoarthritis

    Preclinical

Partnering

Bring us a target, a molecule, or a hard question.

We work with companies, academic groups, and investors who care about rigorous science.

Pharma and biotech

Licensing and co-development for programs from lead optimization onward. We share data early and in full.

Academic labs

Collaborations that turn well-validated biology into drug discovery programs, with clear terms on publication and IP from the start.

Investors

We're glad to walk through our programs, data, and plans in detail with investors who know the field.

Careers

Join the lab.

We're building a team of chemists and biologists who like hard problems and clear data. We hire across discovery, from the first assay to the candidate package.

  • Medicinal chemistry
  • Assay biology
  • Structural biology
  • Computational chemistry
  • DMPK
  • In vivo pharmacology

Send a CV and a short note about work you're proud of to dharbiosciences@gmail.com.

Contact

Talk to us.

One inbox for partnering, collaborations, careers, and press.